KLK3 and prostate cancer: Many patients may choose radiation therapy for treatment of prostate cancer but despite improvements in treatment, progression or recurrence can occur, with approximately 20–47% of men having a rise of prostate specific antigen (PSA) that meets the Phoenix criteria for biochemical failure (BCF) at 15 years post-treatment [2, 3].